title: Economic and Quality of Life Benefits of Anti-VEGF Therapy.
abstract: Vision impairment and blindness create a significant impact on quality of life and loss of productivity. Health care expenditures for vision problems, including direct medical costs and indirect costs for support services and loss of productivity, amount to $139 billion annually. It is projected that by 2020, five million people will have visual impairment due to age related macular degeneration and diabetic macular edema. VEGF inhibitor therapy has been shown to be a cost-effective treatment for age related macular degeneration and diabetic macular edema that has reduced the incidence of vision loss and can reduce the associated economic and societal cost.
authors.affiliation: Shiley Eye Institute and Biomaterials and Tissue Engineering Center, Department of Ophthalmology and Institute for Engineering in Medicine, University of California, San Diego , La Jolla, California 92093, United States.
authors.forename: Nickisa
authors.initials: N
authors.lastname: Hodgson
authors.affiliation: Shiley Eye Institute and Biomaterials and Tissue Engineering Center, Department of Ophthalmology and Institute for Engineering in Medicine, University of California, San Diego , La Jolla, California 92093, United States.
authors.forename: Frances
authors.initials: F
authors.lastname: Wu
authors.affiliation: Shiley Eye Institute and Biomaterials and Tissue Engineering Center, Department of Ophthalmology and Institute for Engineering in Medicine, University of California, San Diego , La Jolla, California 92093, United States.|Department of Ophthalmology, Xijing Hospital, Fourth Military Medical University , Xi'an 710032, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Zhu
authors.affiliation: Shiley Eye Institute and Biomaterials and Tissue Engineering Center, Department of Ophthalmology and Institute for Engineering in Medicine, University of California, San Diego , La Jolla, California 92093, United States.|Department of Ophthalmology, Shanghai First People's Hospital, School of Medicine, Shanghai JiaoTong University , Shanghai 20080, China.
authors.forename: Wenqui
authors.initials: W
authors.lastname: Wang
authors.affiliation: Shiley Eye Institute and Biomaterials and Tissue Engineering Center, Department of Ophthalmology and Institute for Engineering in Medicine, University of California, San Diego , La Jolla, California 92093, United States.
authors.forename: Henry
authors.initials: H
authors.lastname: Ferreyra
authors.affiliation: Shiley Eye Institute and Biomaterials and Tissue Engineering Center, Department of Ophthalmology and Institute for Engineering in Medicine, University of California, San Diego , La Jolla, California 92093, United States.|Veterans Administration Healthcare System , San Diego, California 92093, United States.
authors.forename: Kang
authors.initials: K
authors.lastname: Zhang
authors.affiliation: Zhongshan Opthalmic Center, Sun Yat-sen University , Guangzhou 510060, China.
authors.forename: Jiawei
authors.initials: J
authors.lastname: Wang
mesh_terms: D000068258:Bevacizumab / Q000191:economics / Q000627:therapeutic use; D048909:Diabetes Complications / Q000188:drug therapy / Q000503:physiopathology; D017048:Health Care Costs; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy / Q000503:physiopathology; D008269:Macular Edema / Q000188:drug therapy / Q000503:physiopathology; D011788:Quality of Life; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab
keywords: QALY; VEGF; cost-effectiveness; diabetic macular edema; macular degeneration